Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorPOTIER, L.
dc.contributor.authorROUSSEL, R.
dc.contributor.authorMARRE, M.
dc.contributor.authorBJORNSTAD, P.
dc.contributor.authorCHERNEY, D. Z.
dc.contributor.authorEL BOUSTANY, R.
dc.contributor.authorFUMERON, F.
dc.contributor.authorVENTECLEF, N.
dc.contributor.authorGAUTIER, J. F.
dc.contributor.authorHADJADJ, S.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOHAMMEDI, Kamel
dc.contributor.authorVELHO, G.
dc.date.accessioned2020-07-09T14:10:55Z
dc.date.available2020-07-09T14:10:55Z
dc.date.issued2019-12
dc.identifier.issn1935-5548 (Electronic) 0149-5992 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10278
dc.description.abstractEnOBJECTIVE: Diabetes is the leading cause of nontraumatic lower-extremity amputations (LEAs). Identification of patients with foot ulcers at risk for amputation remains clinically challenging. Plasma copeptin, a surrogate marker of vasopressin, is associated with the risk of cardiovascular and renal complications in diabetes. RESEARCH DESIGN AND METHODS: We assessed the association between baseline plasma copeptin and risk of LEA during follow-up in four cohorts of people with type 1 (GENESIS, n = 503, and GENEDIAB, n = 207) or type 2 diabetes (DIABHYCAR, n = 3,101, and SURDIAGENE, n = 1,452) with a median duration of follow-up between 5 and 10 years. Copeptin concentration was measured in baseline plasma samples by an immunoluminometric assay. RESULTS: In the pooled cohorts with type 1 diabetes (n = 710), the cumulative incidence of LEA during follow-up by increasing tertiles (tertile 1 [TER1], TER2, and TER3) of baseline plasma copeptin was 3.9% (TER1), 3.3% (TER2), and 10.0% (TER3) (P = 0.002). Cox regression analyses confirmed the association of copeptin with LEA: hazard ratio (HR) for 1 SD increment of log[copeptin] was 1.89 (95% CI 1.28-2.82), P = 0.002. In the pooled cohorts of type 2 diabetes (n = 4,553), the cumulative incidence of LEA was 1.1% (TER1), 2.9% (TER2), and 3.6% (TER3) (P < 0.0001). In Cox regression analyses, baseline plasma copeptin was significantly associated with LEA: HR for 1 SD increment of log[copeptin] was 1.42 (1.15-1.74), P = 0.001. Similar results were observed in the cohort with type 2 diabetes for lower-limb revascularization (HR 1.20 [95% CI 1.03-1.39], P = 0.02). CONCLUSIONS: Baseline plasma copeptin is associated with cumulative incidence of LEA in cohorts of people with both type 1 and type 2 diabetes and may help to identify patients at risk for LEA.
dc.language.isoENen_US
dc.subject.enLEHA
dc.title.enPlasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes
dc.title.alternativeDiabetes Careen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.2337/dc19-1062en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31582427en_US
bordeaux.journalDiabetes Careen_US
bordeaux.page2290-2297en_US
bordeaux.volume42en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue12en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03210822
hal.version1
hal.date.transferred2021-04-28T08:46:30Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Diabetes%20Care&amp;rft.date=2019-12&amp;rft.volume=42&amp;rft.issue=12&amp;rft.spage=2290-2297&amp;rft.epage=2290-2297&amp;rft.eissn=1935-5548%20(Electronic)%200149-5992%20(Linking)&amp;rft.issn=1935-5548%20(Electronic)%200149-5992%20(Linking)&amp;rft.au=POTIER,%20L.&amp;ROUSSEL,%20R.&amp;MARRE,%20M.&amp;BJORNSTAD,%20P.&amp;CHERNEY,%20D.%20Z.&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem